Interferon Biology and LAG-3 Shedding in PD-(L)1 plus LAG-3 Immunotherapy

被引：3
|
作者：
Karapetyan, Lilit [1 ,2 ]
Luke, Jason J. [3 ,4 ,5 ]
机构：
[1] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA
[2] Univ S Florida, Dept Oncol Sci, Tampa, FL USA
[3] UPMC Hillman Canc Ctr, Pittsburgh, PA USA
[4] Univ Pittsburgh, Dept Med, Pittsburgh, PA USA
[5] 5150 Ctr Ave,Room 1 27C, Pittsburgh, PA 15232 USA
来源：
CLINICAL CANCER RESEARCH | 2023年 / 29卷 / 05期
关键词：
CELL; RELATLIMAB; NIVOLUMAB;
D O I：
10.1158/1078-0432.CCR-22-3312
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Targeting coinhibitory receptors on dysfunctional T cells may improve response to anti-PD-(L)1 in the IFNy associated T-cell-inflamed tumor microenvironment. The bispecific lymphocyte activation gene 3 (LAG-3) and PD-L1 blocking antibody FS118, potentially through LAG-3 shedding, represents a promising strategy to improve immune checkpoint blockade. Soluble LAG-3 is an intriguing biomarker for LAG-3 drug activity.
引用
收藏
页码：835 / 837
页数：3
相关论文
共 50 条
  • [21] Advances in understanding the role of immune checkpoint LAG-3 in tumor immunity: a comprehensive review
    Luo, Yingzhe
    Cai, Xuebin
    Yang, Biao
    Lu, Facheng
    Yi, Cheng
    Wu, Guoyu
    FRONTIERS IN ONCOLOGY, 2024, 14
  • [22] PD-1 and LAG-3 Dominate Checkpoint Receptor-Mediated T-cell Inhibition in Renal Cell Carcinoma
    Zelba, Henning
    Bedke, Jens
    Hennenlotter, Joerg
    Mostboeck, Sven
    Zettl, Markus
    Zichner, Thomas
    Chandran, Anoop
    Stenzl, Arnulf
    Rammensee, Hans-Georg
    Gouttefangeas, Cecile
    CANCER IMMUNOLOGY RESEARCH, 2019, 7 (11) : 1891 - 1899
  • [23] Cutting-Edge: Preclinical and Clinical Development of the First Approved Lag-3 Inhibitor
    Chocarro, Luisa
    Bocanegra, Ana
    Blanco, Ester
    Fernandez-Rubio, Leticia
    Arasanz, Hugo
    Echaide, Miriam
    Garnica, Maider
    Ramos, Pablo
    Pineiro-Hermida, Sergio
    Vera, Ruth
    Escors, David
    Kochan, Grazyna
    CELLS, 2022, 11 (15)
  • [24] LAG-3 Protein Expression in Non-Small Cell Lung Cancer and Its Relationship with PD-1/PD-L1 and Tumor-Infiltrating Lymphocytes
    He, Yayi
    Yu, Hui
    Rozeboom, Leslie
    Rivard, Christopher J.
    Ellison, Kim
    Dziadziuszko, Rafal
    Suda, Kenichi
    Ren, Shengxiang
    Wu, Chunyan
    Hou, Likun
    Zhou, Caicun
    Hirsch, Fred R.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (05) : 814 - 823
  • [25] FS118, a Bispecific Antibody Targeting LAG-3 and PD-L1, Enhances T-Cell Activation Resulting in Potent Antitumor Activity
    Kraman, Matthew
    Faroudi, Mustapha
    Allen, Natalie L.
    Kmiecik, Katarzyna
    Gliddon, Daniel
    Seal, Claire
    Koers, Alexander
    Wydro, Mateusz M.
    Batey, Sarah
    Winnewisser, Julia
    Young, Lesley
    Tuna, Mihriban
    Doody, Jacqueline
    Morrow, Michelle
    Brewis, Neil
    CLINICAL CANCER RESEARCH, 2020, 26 (13) : 3333 - 3344
  • [26] A Phase 1 First-in-Human Study of FS118, a Tetravalent Bispecific Antibody Targeting LAG-3 and PD-L1 in Patients with Advanced Cancer and PD-L1 Resistance
    Yap, Timothy A.
    LoRusso, Patricia M.
    Wong, Deborah J.
    Hu-Lieskovan, Siwen
    Papadopoulos, Kyriakos P.
    Holz, Josefin-Beate
    Grabowska, Urszula
    Gradinaru, Cristian
    Leung, Kin-Mei
    Marshall, Sylwia
    Reader, Claire S.
    Russell, Roslin
    Sainson, Richard C. A.
    Seal, Claire J.
    Shepherd, Christopher J.
    Germaschewski, Fiona
    Gliddon, Daniel
    Stern, Omer
    Young, Lesley
    Brewis, Neil
    Kayitalire, Louis
    Morrow, Michelle
    CLINICAL CANCER RESEARCH, 2023, 29 (05) : 888 - 898
  • [27] Prognostic Value of Lymphocyte Activation Gene-3 (LAG-3) Expression in Esophageal Squamous Cell Carcinoma
    Zhang, Yu
    Liu, Yong-dong
    Luo, Yi-ling
    Liu, Bin-liu
    Huang, Qi-tao
    Wang, Fang
    Zhong, Qian
    JOURNAL OF CANCER, 2018, 9 (22): : 4287 - 4293
  • [28] Profiling the inhibitory receptors LAG-3, TIM-3, and TIGIT in renal cell carcinoma reveals malignancy
    Takamatsu, Kimiharu
    Tanaka, Nobuyuki
    Hakozaki, Kyohei
    Takahashi, Ryohei
    Teranishi, Yu
    Murakami, Tetsushi
    Kufukihara, Ryohei
    Niwa, Naoya
    Mikami, Shuji
    Shinojima, Toshiaki
    Sasaki, Takashi
    Sato, Yusuke
    Kume, Haruki
    Ogawa, Seishi
    Kakimi, Kazuhiro
    Kamatani, Takashi
    Miya, Fuyuki
    Tsunoda, Tatsuhiko
    Aimono, Eriko
    Nishihara, Hiroshi
    Sawada, Kazuaki
    Imamura, Takeshi
    Mizuno, Ryuichi
    Oya, Mototsugu
    NATURE COMMUNICATIONS, 2021, 12 (01)
  • [29] Update on lymphocyte-activation gene 3 (LAG-3) in cancers: from biological properties to clinical applications
    Zhao, Lishu
    Wang, Hao
    Xu, Kandi
    Liu, Xinyue
    He, Yayi
    CHINESE MEDICAL JOURNAL, 2022, 135 (10) : 1203 - 1212
  • [30] Impact of LAG-3/FGL1 pathway on immune evasive contexture and clinical outcomes in advanced urothelial carcinoma
    Yoshida, Takashi
    Nakamoto, Takahiro
    Atsumi, Naho
    Ohe, Chisato
    Sano, Takeshi
    Yasukochi, Yoshiki
    Tsuta, Koji
    Kinoshita, Hidefumi
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2024, 12 (07) : 1 - 14
12345